Prostate cancer statistics 2025

Prostate cancer statistics 2025

Dr. Gil MorganThe OncoAlert Network

CA: A Cancer Journal for Clinicians

Read the paper in CA: A Cancer Journal for Clinicians

Dr. Gil Morgan in conversation with Mr. Tyler Kratzer of the American Cancer Society, lead author of Prostate Cancer Statistics 2025, published in CA: A Cancer Journal for Clinicians.

More on genitourinary cancers

Everything on genitourinary cancers

DASL-HiCaP: Darolutamida melhora a sobrevida livre de metástases no câncer de próstata | ESMO 2026
Expert pick. ESMO 2026.
LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26
Dr. Daniel Heng. Trial update. ESMO 2026.
Does Adding Nivolumab Help in MIBC? CA017-078/ ENERGIZE Explained | Andrea Necchi | ESMO 2026
Dr. Andrea Necchi. ESMO 2026. Trial update.
VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
Dr. Tom Powles. Trial update. ESMO 2026.
Can triplet combinations improve outcomes in advanced urothelial cancer?
Sara Coca Membribes. ESMO 2026. Expert pick. Day 1.
Cribiform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)
Publication pick. Nature Reviews Urology. October 15, 2026.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details

Prostate cancer statistics 2025

More on genitourinary cancers

DASL-HiCaP: Darolutamida melhora a sobrevida livre de metástases no câncer de próstata | ESMO 2026

LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26

Does Adding Nivolumab Help in MIBC? CA017-078/ ENERGIZE Explained | Andrea Necchi | ESMO 2026

VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC

Can triplet combinations improve outcomes in advanced urothelial cancer?

Cribiform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)

The week in oncology, in your inbox